Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HK1 | P19367 | 1/20 | 0.40 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012568 | 0.93 | MAPT (0.41) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3065870 | 0.93 | HPGD (0.43) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL749155 | 0.85 | CRHBP (0.53) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3116170 | 0.81 | MAPT (0.34) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3116165 | 0.80 | HPGD (0.36) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3091919 | 0.78 | ALDH1A1 (0.47) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL3083218 | 0.77 | MAPT (0.55) | HPGDMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL3073201 | 0.77 | ALDH1A1 (0.50) | HPGDMAPTALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4870477 | 0.76 | CRHBP (0.45) | HPGDMAPTALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL4013159 | 0.75 | KMT2A (0.62) | MAPTCA2CA5AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| EP-2144893-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2010-01-20 | — | — | EP | disclosed |
| EP-2074107-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008137816-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008057254-A2 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | HPGD 131/4885MAPT 3889/4885ALDH1A1 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.